Event

The treatment goals of alleviating symptoms and reducing exacerbation risk in management of COPD remain unchanged but the updated guidelines give more clarity on which patients are suited for treatment with bronchodilators and which may require additional therapy. The industry theatre will focus on the importance of dual bronchodilator therapy (LAMA/LABA) for patients with persistent symptoms and will explore the latest evidence to support single inhaler triple therapy (ICS/LAMA/LABA) for patients with at least 1 moderate/severe exacerbation in the prior year. Adoption of these recommendations allows physicians to use a more personalised treatment approach for their COPD patients.